(-0.05%) 5 476.00 points
(-0.08%) 38 787 points
(-0.02%) 19 918 points
(0.30%) $80.57
(1.18%) $2.82
(0.24%) $2 334.60
(-0.17%) $29.34
(-0.21%) $968.90
(0.01%) $0.932
(-0.14%) $10.64
(0.06%) $0.788
(-1.87%) $86.80
@ $1 048.72
Išleistas: 17 birž. 2024 @ 20:41
Grąža: -0.32%
Ankstesnis signalas: birž. 17 - 16:50
Ankstesnis signalas:
Grąža: 1.72 %
Live Chart Being Loaded With Signals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion...
Stats | |
---|---|
Šios dienos apimtis | 431 753 |
Vidutinė apimtis | 426 579 |
Rinkos kapitalizacija | 113.28B |
EPS | $6.70 ( Q1 | 2024-05-02 ) |
Kita pelno data | ( $10.57 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
30.85 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $23.45 (2.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Brown Michael S | Buy | 1 535 | Common Stock |
2024-06-14 | Brown Michael S | Sell | 1 535 | Common Stock |
2024-06-14 | Brown Michael S | Sell | 1 535 | Non-Qualified Stock Option (right to buy) |
2024-06-11 | Schleifer Leonard S | Sell | 7 321 | Common Stock |
2024-06-11 | Schleifer Leonard S | Sell | 1 743 | Common Stock |
INSIDER POWER |
---|
-43.13 |
Last 100 transactions |
Buy: 248 776 | Sell: 625 256 |
Tūris Koreliacija
Regeneron Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
KPLT | 0.823 |
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Regeneron Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Regeneron Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $13.12B |
Bruto pelnas: | $11.30B (86.16 %) |
EPS: | $37.05 |
FY | 2023 |
Pajamos: | $13.12B |
Bruto pelnas: | $11.30B (86.16 %) |
EPS: | $37.05 |
FY | 2022 |
Pajamos: | $12.17B |
Bruto pelnas: | $10.61B (87.18 %) |
EPS: | $40.51 |
FY | 2021 |
Pajamos: | $16.07B |
Bruto pelnas: | $13.63B (84.83 %) |
EPS: | $76.40 |
Financial Reports:
Symbol | Period | Year | Title |
---|---|---|---|
REGN | Q4 | 2023 | Financial Report for REGN - Q4 2023 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.